Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Feb 18.
Published in final edited form as: J Clin Endocrinol Metab. 2005 Feb;90(2):611–614. doi: 10.1210/jc.2004-1719

Growth Hormone Releasing Peptide -2 (GHRP-2), like ghrelin, increases food intake in healthy men

Blandine Laferrère 1, Cynthia Abraham 2, Colleen D Russell 3, Cyril Y Bowers 4
PMCID: PMC2824650  NIHMSID: NIHMS176333  PMID: 15699539

Abstract

GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor. Ghrelin has been shown to have two major effects, stimulating both GH secretion and appetite/meal initiation. GHRP-2 has been extensively studied for its utility as a growth hormone secretagogue (GHS). Animal studies have shown its effect on food intake. However, whether GHRP-2 can also stimulate appetite in humans when administered acutely is not known. We subcutaneously infused 7 lean, healthy males with GHRP-2 (1μg/kg/h) or saline for 270 minutes and then measured their intake of an ad libitum, buffet-style meal. Similar to what has been reported for ghrelin administration, our subjects ate 35.9±10.9 % more when infused with GHRP-2 vs. saline, with every subject increasing their intake even when calculated per kg body weight (136.0±13.0 kJ/kg vs 101.3±10.5 kJ/kg, p=0.008). The macronutrient composition of consumed food was not different between conditions. As expected, serum GH levels rose significantly during GHRP-2 infusion (AUC 5550±1090 μg/L/240 min vs. 412±161 μg/L/240 min, p=0.003). These data are the first to demonstrate that GHRP-2, like ghrelin, increases food intake, suggesting that GHRP-2 is a valuable tool for investigating ghrelin effects on eating behavior in humans.

Introduction

Ghrelin, the recently identified peptide secreted by gastric endocrine cells (1), has attracted much interest for its dual effects. This endogenous ligand for the growth hormone secretagogue receptor (GHS-R) which was cloned in 1996 (2) regulates growth hormone (GH) release (3). Ghrelin also appears to play a role in the regulation of food intake and energy balance. When administered either centrally or peripherally to rodents, ghrelin increases food intake and body weight (4,5). Interestingly, its effects on food intake are independent of GH secretion (4,6-8) and appear to be mediated via the NPY/Agouti gene-related protein (AGRP) neurons in the hypothalamic arcuate nucleus (9,10). Peripheral ghrelin administration has recently been shown to stimulate food intake in lean, healthy men and women (11) and in cancer patients (12).

Data suggest that circulating ghrelin is also implicated in meal to meal regulation. Ghrelin levels increase in anticipation of a meal (13) and are suppressed by food ingestion (13, 14), but the underlying mechanisms are not known. The meal-related suppression of ghrelin is proportional to the carbohydrate (CHO) content of the meal but does not appear to be directly related to glucose or insulin (14,15), although insulin administration decreases ghrelin (16).

Serum ghrelin levels vary as a function of energy balance. Ghrelin levels are increased in anorexia (17) and decreased in obesity (18). Thus, it is possible that ghrelin may be an important player in food intake behavior and perhaps in chronic over- and undernutrition as well (19). Because of its dual effects, ghrelin may be a critical hormonal signal of nutritional status to the somatotropic axis, playing a role in integrating energy balance with the growth process (20).

Ghrelin is not available for long-term studies in human subjects in the United States, however, the synthetic GHS-R agonist GHRP-2 (DalaDßNalAlaTrpDPheLysNH2) is available for clinical studies. GHRP-2 belongs to a family of GHS(s) discovered in the 1980's and extensively studied for their effect on GH release (21). Despite the very different chemistry of natural ghrelin and synthetic GHS, evidence strongly and increasingly supports that they have the same biological actions. Like ghrelin, GHS(s) increase food intake and body weight in rodents (22). GHRP-2 has been shown to increase appetite ratings in children with idiopathic GH treated chronically with oral GHRP-2 (23).

The aim of this study was to investigate whether GHRP-2 stimulates food intake in healthy human subjects. Similar to the study by Wren et al. (11) which used ghrelin, we tested the effect of a short-term subcutaneous (sc) infusion of GHRP-2 on food intake during a buffet meal.

Methods

Subjects

Seven lean men, (age 26.0 ± 1.6 year, BMI 21.5 ± 1.7 kg/m2, fat mass 14.4 ± 1.1 % by anthropometrics, weight stable, healthy, on no medications, non-smoking, non-dieting, without any eating disorder, participated in the study. The Institutional Review Board of St. Luke's/Roosevelt Hospital approved the study protocol and informed written consent was obtained prior to inclusion in the study. A screening session included a full physical exam, routine laboratory tests, a taste test and a test meal. Subjects had to rate their liking of the food a ‘5’. or more on average (on a scale 0-7) and had to eat at least 2090 kJ at the screening test meal.

Study Design

Subjects were studied after an overnight fast on two non-consecutive days separated by at least a week. In a randomized, double-blind fashion, GHRP-2 (1 μg/kg/h) or placebo was administered for the entire duration of the experiment (including meal time) via sc catheter attached to a pump (Minimed 508). Blood was collected for subsequent hormone measurement through an iv catheter placed in the forearm, sampled every 30 minutes until the beginning of the meal. The buffet meal included several choices of food served in excess to accommodate any appetite. While eating in the laboratory, the subjects were observed with a camera to ensure their safety and that they did not dispose of the food in any other way than eating. A fixed, standard test breakfast was given 120 minutes after the beginning of the infusion and the ad libitum lunch was offered at 240 min. The breakfast consisted of 1.5 English Muffins, 5 g of butter, and 125 ml of apple juice (1254 kJ, 65% CHO, 4% protein, 31% fat). Prior to the buffet lunch, subjects listened to taped instruction to ‘eat as much as they wanted’. The items served during the buffet lunch were pasta, bread rolls, peas and carrots, chocolate chip cookies, apple sauce, chicken nuggets and breaded fillets, and water. Food was weighed before and after the meal and caloric intake calculated. After the meal, the infusion was stopped. Visual analogue scales (VAS, from 0 ‘not at all’ to 150 mm ‘extremely’) to assess hunger and fullness rating were administered prior to starting the infusion, before and after breakfast, and before and after completion of the lunch meal. The positions of the marks on the 150 mm scale were measured in mm by a blinded investigator.

Assays

Serum GH concentrations were measured in duplicate by a radioisotopic kit for quantitative determination of HGH from Nichols Institute Diagnostic (San Juan, CA). The assay sensitivity was 0.2 μg/L and the median intra- and interassay coefficients of variation were 2.9% and 7.5% respectively. Serum cortisol levels were measured by radioimmunoassay (kit from DSL, Webster, TX). The assay sensitivity was 0.11 ng/dl. The median intra- and interassay variation was 3.8% and 5.9% respectively. Blood collection was incomplete for one subject therefore data on 6 subjects are reported.

Statistics

Comparison between GHRP-2 and placebo was done by a paired t-test for all variables. Hormonal response was assessed as area under the curve (AUC) as measured by the trapezoidal method. A p value of 0.05 was used for level of significance. Data are presented as mean ± SEM unless otherwise stated. SPSS version 11.5 was used for statistical analysis.

Results

No side effects from the infusion were reported. Food intake at the buffet meal was increased by 35.9±10.9 % (range 12 to 95%) with GHRP-2 compared to placebo. Each and every subject responded to the GHRP-2 infusion by increasing their food intake, regardless of the amount of food eaten during the saline control experiment (Figure 1). The total amount of calories eaten was greater with GHRP-2 than with placebo (9409±1229 kJ vs. 7118±1078 kJ, p=0.004) as were the kJ eaten per kg of body weight (136±13 kJ/kg vs. 101±10 kJ/kg, p=0.008). Subjects ate more CHO (58±14 g, p=0.006), protein (17±4 g, p=0.005) and fat (38±10 g, p=0.008) with GHRP-2 than placebo and the proportion of calories obtained from each nutrient was not different between the 2 conditions (results not shown). The duration of the ad libitum meal was the same with and without the GHRP-2 (30 ± 8 min vs. 32±6 min, p=0.667). Thus the food intake per interval (calories eaten during the meal divided by the duration of the meal) was greater, but not significantly, with GHRP-2 than with placebo (322±33 kJ/min vs. 276±38 kJ/min, p=0.179). Based on the VAS, baseline hunger and fullness ratings were not different between conditions. However, during the GHRP-2 infusion, subjects felt hungrier (112.6±7.5 mm vs. 89.7±12.2, p=0.013) before lunch and showed a trend to be fuller after lunch (134.1±6.0 mm vs. 118.6±10.3 mm, p=0.054).

Figure 1. Effect of GHRP-2 on food intake.

Figure 1

Individual changes in energy intake from a buffet meal, inset graph shows mean±sem.

Levels of hGH increased significantly during the GHRP-2 infusion, reaching a plateau of 36.4±7.0 μg/L 60 minutes after the beginning of the infusion. GH levels were significantly more elevated during the infusion of GHRP-2 (AUC 5550±1090 μg/L/240 min vs. 412±161μg/L/240 min, p=0.003) (Figure 2). Serum cortisol levels increased transiently with GHRP-2 compared to placebo (results not shown).

Figure 2. GH levels during GHRP-2 infusion.

Figure 2

GHRP-2 (1μg/kg/h) and saline infusion started at 0 min and breakfast was served at 120 min.

Discussion

These are the first data to demonstrate that peripheral administration of GHRP-2 increases food intake in humans. The effect of GHRP-2 is robust and elicited an increase of food intake in all subjects tested. Subjects reported being hungrier while receiving GHRP-2. The magnitude of the effect of GHRP-2 on food intake (+35%) is comparable to that of ghrelin previously shown to increase food intake by 28% in healthy subjects (11) and by 31% in cancer patients (12). The effect of 1 μg/kg/h of GHRP-2 is comparable to the effect of ghrelin (5 pmol/kg/min) not only on food intake, but also on GH release. In Wren's (5) study (also in healthy lean subjects), ghrelin raised GH to similar levels (about 35 μg/L). Therefore, ghrelin or the ghrelin mimetic GHRP-2, when administered peripherally, is able to induce significant acute changes of similar magnitude in both GH levels and food intake behavior.

The hormonal regulation of food intake can be divided into long-term fat storage signals (leptin and insulin) and short-term meal initiation and satiety signals (ghrelin, CCK, and PYY). Ghrelin, although mainly secreted in the stomach, is believed to act centrally on the NPY-AGRP neurons of the arcuate nucleus (9,10). The mechanism for and amount of circulating peripheral ghrelin reaching these hypothalamic neurons is unclear. In rodents, both centrally and peripherally administered ghrelin (4) or GHS(s) (21,22) stimulate food intake. Evidence suggests that the spontaneous variation of endogenous serum ghrelin concentrations may play a role in intermeal duration, the recurrence of hunger and subsequent meal size (24). The postprandial suppression of ghrelin is proportional to meal size, but does not predict intermeal interval (25). Studies based on morning fasting serum levels of ghrelin have found no positive (25) or negative (26) relationship between fasting plasma ghrelin levels and ad libitum food intake. Whether fasting total (n-octanoyl plus desoctanoyl) ghrelin levels are the best marker for subsequent food intake is unclear. Furthermore, the integrated 24 h ghrelin release may be a better predictor of short-term energy balance/ food intake (27), just as integrated 24 h leptin levels are a better index of daytime food intake and insulin secretion (28) than morning fasting leptin levels. Both our data with the GHRP-2 and others with ghrelin (11,12) show that a peripheral infusion of these orexigenic peptides can elicit a robust acute change in food intake behavior in humans. This suggests, although does not prove, a possible role for peripheral circulating ghrelin in the meal to meal regulation (13, 25). It is unlikely, however, that simple alterations in the serum level of ghrelin alone dictate the magnitude or type of downstream effects via activation of central and peripheral receptors (29).

As previously reported (30), a subcutaneous infusion of GHRP-2 for 270 minutes is safe. Accordingly, no adverse side effects were reported during a 30-day sc continuous infusion of GHRP-2 (30) or 12 month oral administration of the drug in children (23).

Two studies revealed that chronic administration of GHRP-2 to short stature children with various degrees of GH deficiency induces a sustained enhancement in the rate of linear growth (23,31). This suggests the possibility that the acute effect of GHRP-2 on food intake observed in our study might result in a state of positive energy balance, were GHRP-2 administered chronically. Carefully designed and optimized chronic studies, including detailed body composition and food intake monitoring, will help to demonstrate the long-term effects of GHS(s) on food intake and body weight. Although GHRP-2 increased GH significantly, it is unlikely, judging from the results of rhGH alone, that this increase in GH levels is responsible for the acute changes in food intake in this study. In addition, the hypothalamic pathway and mechanism by which GHS(s) enhance food intake are distinctly different from those by which GHS(s) enhance GH secretion (4,7,33,34). Additionally, the stimulation of food intake by ghrelin or GHS persists in GH-deficient rats (10).

In most reports published thus far, the bioactive ghrelin molecule was not measured in human plasma and large pharmacological, rather than physiological, doses of ghrelin were administered. Other relevant future objectives to better understand the physiology and pathophysiology of the ghrelin system in humans will require more specific and frequent measurement of plasma ghrelin levels as well as determination of how closely the pharmacological and physiological actions of ghrelin parallel each other. GHRP-2, like ghrelin, is a useful tool for clinical study to help understand the complexity of food intake behavior regulation in humans.

Acknowledgments

NIH DK 02572-01 and GCRC RR 00645 and 05096, ORC 26687. We thank MINIMED for lending us the infusion pump and all the pump supplies.

Contributor Information

Blandine Laferrère, Obesity Research Center, St Luke's Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025.

Cynthia Abraham, Obesity Research Center, St Luke's Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025.

Colleen D. Russell, Obesity Research Center, St Luke's Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025

Cyril Y. Bowers, Tulane University Health Sciences Center, New Orleans, Louisiana 70112

References

  • 1.Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature. 1999;402(6762):656–660. doi: 10.1038/45230. [DOI] [PubMed] [Google Scholar]
  • 2.Howard AD, Feighner SD, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Van der Ploeg LH, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–977. doi: 10.1126/science.273.5277.974. [DOI] [PubMed] [Google Scholar]
  • 3.Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85:4908–4911. doi: 10.1210/jcem.85.12.7167. [DOI] [PubMed] [Google Scholar]
  • 4.Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913. doi: 10.1038/35038090. [DOI] [PubMed] [Google Scholar]
  • 5.Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DC, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141:4325–4328. doi: 10.1210/endo.141.11.7873. [DOI] [PubMed] [Google Scholar]
  • 6.Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsakura S. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194–198. doi: 10.1038/35051587. [DOI] [PubMed] [Google Scholar]
  • 7.Torsello A, Ghe C, Bresciani E, Catapano F, Ghigo E, Deghengi R, Locatelli V, Mucciolo G. Short ghrelin peptides neither displace ghrelin, binding in vitro nor stimulate GH release in vivo. Endocrinology. 2002;143:1968–1971. doi: 10.1210/endo.143.5.8894. [DOI] [PubMed] [Google Scholar]
  • 8.Chen C. Growth hormone secretagogue actions on the pituitary gland: multiple receptors for multiple ligands? Clin Exp Pharmacol Physiol. 2000;27:323–329. doi: 10.1046/j.1440-1681.2000.03258.x. [DOI] [PubMed] [Google Scholar]
  • 9.Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes. 2001;50:2438–2443. doi: 10.2337/diabetes.50.11.2438. [DOI] [PubMed] [Google Scholar]
  • 10.Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50(2):227–232. doi: 10.2337/diabetes.50.2.227. [DOI] [PubMed] [Google Scholar]
  • 11.Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5995. doi: 10.1210/jcem.86.12.8111. [DOI] [PubMed] [Google Scholar]
  • 12.Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2832–2836. doi: 10.1210/jc.2003-031768. [DOI] [PubMed] [Google Scholar]
  • 13.Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–1719. doi: 10.2337/diabetes.50.8.1714. [DOI] [PubMed] [Google Scholar]
  • 14.Caixas A, Bashore C, Nash W, Pi-Sunyer FX, Laferrère B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab. 2002;87:1902–1906. doi: 10.1210/jcem.87.4.8538. [DOI] [PubMed] [Google Scholar]
  • 15.Schaller G, Scmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin. A double-blind, placebo controlled clamp study. 2003;52:16–20. doi: 10.2337/diabetes.52.1.16. [DOI] [PubMed] [Google Scholar]
  • 16.Saad MF, bernaba B, Hwu CM, Jinagouda S, Fahmi S, Kogosov E, Boyadjian R. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab. 2002;87(8):3997–4000. doi: 10.1210/jcem.87.8.8879. [DOI] [PubMed] [Google Scholar]
  • 17.Otto B, Cuntz U, Fruehauf E, Warwarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnart P, Fichter M, Tschop M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol. 2001;145:669–673. [PubMed] [Google Scholar]
  • 18.Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–709. doi: 10.2337/diabetes.50.4.707. [DOI] [PubMed] [Google Scholar]
  • 19.Wang G, Lee HM, Englander E, Greeley GH. Ghrelin-not just another stomach hormone. Regul Pept. 2002;105:75–81. doi: 10.1016/s0167-0115(02)00012-5. [DOI] [PubMed] [Google Scholar]
  • 20.Heiman ML, Tschop M. Ghrelin provides the calories that growth hormone requires for growth and repair. Topic Endocrinol Suppl. 2001;2:39–40. [Google Scholar]
  • 21.Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–1545. doi: 10.1210/endo-114-5-1537. [DOI] [PubMed] [Google Scholar]
  • 22.Kuriyama H, Hotta M, Wakabayashi I, Shibasaki T. A 6-day intracerebro-ventricular infusion of the growth hormone-releasing peptide KP-102 stimulates food intake in both non-stressed and intermittently-stressed rats. Neurosci Lett. 2000;282(12):109–112. doi: 10.1016/s0304-3940(00)00882-x. 17. [DOI] [PubMed] [Google Scholar]
  • 23.Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab. 2003;16:981–985. doi: 10.1515/jpem.2003.16.7.981. [DOI] [PubMed] [Google Scholar]
  • 24.Erdmann J, Topsch R, Lippl F, Gussmann P, Schusdziarra V. Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin and glucose. J Clin Endocrinol Metab. 2004;89:3048–3054. doi: 10.1210/jc.2003-031610. [DOI] [PubMed] [Google Scholar]
  • 25.Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab. 2004;89(3):1319–1324. doi: 10.1210/jc.2003-031267. [DOI] [PubMed] [Google Scholar]
  • 26.Salbe AD, Tschop MH, DelParigi A, Venti CA, Tataranni PA. Negative relationship between fasting plasma ghrelin concentrations and ad libitum food intake. J Clin Endocrinol Metab. 2004;89(6):2951–2956. doi: 10.1210/jc.2003-032145. [DOI] [PubMed] [Google Scholar]
  • 27.Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: ghrelin and the regulation of energy balance- a hypothalamic perspective. Endocrinology. 2001;142(10):4163–4169. doi: 10.1210/endo.142.10.8490. [DOI] [PubMed] [Google Scholar]
  • 28.Havel PJ, Towsend R, Chaump L, Teff K. High-fat meals reduce 24-h circulating leptin concentrations in women. Diabetes. 1999;48(20):334–341. doi: 10.2337/diabetes.48.2.334. [DOI] [PubMed] [Google Scholar]
  • 29.Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002;440(23):235–254. doi: 10.1016/s0014-2999(02)01432-2. 12. [DOI] [PubMed] [Google Scholar]
  • 30.Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290–2300. doi: 10.1210/jc.2003-031799. [DOI] [PubMed] [Google Scholar]
  • 31.Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168–1172. doi: 10.1210/jcem.83.4.4744. [DOI] [PubMed] [Google Scholar]
  • 32.Okada K, Ishii S, Minami S, Sugihara H, Shibasaki T, Wakabayashi I. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology. 1996;137(11):5155–5158. doi: 10.1210/endo.137.11.8895390. [DOI] [PubMed] [Google Scholar]
  • 33.Locke W, Kirgis HD, Bowers CY, Abdoh AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci. 1995;56:1347–1352. doi: 10.1016/0024-3205(95)00087-9. [DOI] [PubMed] [Google Scholar]
  • 34.Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280:132–138. doi: 10.1006/bbrc.2000.4065. [DOI] [PubMed] [Google Scholar]

RESOURCES